Skip to main content

Branded

  • As innovaters prep for patent cliff, generics prosper from patent losses

    A whole slew of drugs will lose patent protection this year, opening up opportunities for generic drug makers to market their own versions. Most notable among these is Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin), the world’s top-selling drug, with U.S. sales of $7 billion during the 12 months ended September 2010, according to IMS Health.


  • ReportersNotebook — Chain Pharmacy, 2/28/11

    SUPPLIER NEWS — Drug maker Valeant Pharmaceuticals International has acquired U.S. and Canadian rights to certain formulations of a GlaxoSmithKline drug used to treat cold sores. Valeant acquired the rights to nonophthalmic topical formulations of Zovirax (acyclovir) from GSK for $300 million through its Canadian subsidiary, Biovail Labs.



  • Report: Exclusivity period for biotech drugs may be reduced to seven years

    WASHINGTON — The Obama administration’s proposed budget for 2012 contains an item that could change the game for biosimilars, according to published reports.

    According to the reports, the administration would lower the 12-year data exclusivity period for biotech drugs mandated in the healthcare-reform law to seven years.

  • FDA OKs Abilify as maintenance treatment for bipolar disorder

    PRINCETON, N.J. — The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.

    The FDA approved Abilify (aripiprazole), made by Bristol-Myers Squibb and Otsuka Pharmaceutical, as an adjunct to lithium or valproate for maintenance treatment of bipolar I disorder.

  • Auralgan otic solution seized by government officials

    SILVER SPRING, Md. — The Food and Drug Administration has seized supplies of a drug used to treat ear infections, under a program the agency started to remove unapproved drugs from the market.

    The FDA announced the seizure of about $16.5 million worth of Auralgan otic solution made by Brooks, Ky.-based Integrated Commercialization Solutions. Chapel Hill, N.C.-based Deston Therapeutics manufactures the drug, while ICS warehouses it.

  • Savient announces executive appointments

    EAST BRUNSWICK, N.J. — Savient Pharmaceuticals announced changes to its management team as it gears up for the commercial launch of its chronic gout treatment.

    The drug maker appointed Louis Ferrari as its SVP corporate development, Christine Mikail as SVP and Stephen Davies as chief information officer and group VP.

  • NACDS RxImpact Day 2011 takes aim at new lawmakers

    WASHINGTON — The National Association of Chain Drug Stores and its members from across the country once again are flocking to Capitol Hill for RxImpact Day, a groundbreaking, two-day event that enables pharmacists to meet with members of Congress to discuss the vital role of retail pharmacy within the U.S. healthcare system and its ability to help reduce annual healthcare costs.

  • Sanofi-Aventis obtains Genzyme for $20.1 billion

    CAMBRIDGE, Mass. — French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

X
This ad will auto-close in 10 seconds